Stock Analysis·← Pickers

SPTX

Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. Common Stock (SPTX) is currently in a range/mixed trend. RSI is at 53.2, with 1/3 trend checks passing.

Price
$20.45
2026-07-16
Trend score
1/3
Range / Mixed
RSI (14)
53.2
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

SPTX with MA50 and MA200

22.5220.7018.8817.0715.2505/0105/2006/0806/2607/15
SPTX2026-05-012026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$18.11+12.93% vs price
MA200
Distance unavailable
RSI (14)
53.2Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for SPTX

Seaport Therapeutics, Inc. Common Stock (SPTX) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $20.45, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 12.9%.

Momentum and stretch context

SPTX currently has an RSI reading of 53.2, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the SPTX chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Sector
Healthcare
Industry
Biotechnology
CEO
Daphne Zohar
Employees
58
Market cap
$1.09B
Beta
0.00
52-week range
$14.85 – $23.00
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
1 May 2026
ISIN
US81221K1088
CUSIP
81221K108
Company profile data from Financial Modeling Prep. SPTX listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about SPTX

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.

SPTX Stock Analysis: Range/Mixed trend, RSI 53 | MyStockHarbor